Form 4: BioXcel Therapeutics Executive Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
BioXcel Therapeutics' Chief Legal Officer, Javier Rodriguez, sold a portion of his holdings in company stock under a pre-arranged 10b5-1 trading plan.
Summary
- Javier Rodriguez, Chief Legal Officer of BioXcel Therapeutics, executed multiple transactions involving the company's common stock.
- These transactions included the vesting of restricted stock units (RSUs) and the subsequent sale of some of the underlying shares.
- On December 14, 2024, 521 RSUs vested, and on December 15, 2024, 562 RSUs vested.
- Following the vesting, Mr. Rodriguez sold 210 shares at $0.355 and 220 shares at $0.3567 on December 16, 2024.
- These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- After these transactions, Mr. Rodriguez directly owns 24,423 shares of BioXcel Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither particularly positive nor negative.
Risks
- Sales by company executives can sometimes be perceived negatively by the market, potentially impacting the stock price.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their stock sales in a compliant manner.
- The vesting schedules for RSUs are typical for executive compensation packages, often including a cliff vesting period followed by regular vesting intervals.
- The sale of shares by executives is a normal part of the market and is not unusual, especially when part of a pre-arranged plan.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Javier Rodriguez was granted 8,337 RSUs, vesting over time. |
| 2023-03-15 | Javier Rodriguez was granted 9,000 RSUs, vesting over time. |
| 2023-12-14 | Javier Rodriguez adopted a Rule 10b5-1 trading plan. |
| 2024-12-14 | 521 RSUs vested. |
| 2024-12-15 | 562 RSUs vested. |
| 2024-12-16 | 210 shares were sold at $0.355 and 220 shares were sold at $0.3567. |
| 2024-12-17 | Form 4 filing date. |
Keywords
BioXcel Therapeutics, BTAI, Javier Rodriguez, insider trading, Form 4, restricted stock units, Rule 10b5-1, stock sale, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.